ClinicalTrials.gg
CompletedNCT05611567Updated Nov 10, 2022

Endoscopic Gastric Plication Using the POSE2.0 Technique for Management of Fatty Liver Disease

An interventional study of POSE2.0 procedure and Life style and behavioral intervention in Non-Alcoholic Fatty Liver Disease and Obesity, sponsored by Emirates Health Services (EHS). Completed at 1 site in United Arab Emirates. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-10.

Sponsored by Emirates Health Services (EHS) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Jan 2020, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary Obesity Surgery Endoluminal 2.0, or POSE 2.0, (USGI Medical, San Clemente, CA) creates full-thickness plications of gastric tissue endoscopically to shorten the stomach and narrow its aperture for weight loss in patients with obesity. Adults with obesity and non-alcoholic NAFLD were allocated based on preference and motivation to undergo the POSE 2.0 procedure with lifestyle modification or lifestyle modification alone to study the impact of the POSE2.0 procedures on NAFLD parameters and metabolic profile. Co-primary endpoints included improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary endpoints included total body weight loss (TBWL), change in serum measures of hepatic steatosis and insulin resistance, and device safety.

02

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Obesity
03

In context

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

This study's enrollment of 42 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.

Browse Non-alcoholic Fatty Liver Disease studies →

Lead sponsor

Emirates Health Services (EHS) is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form.
  2. Subject agrees to be compliant with study requirements and adhere to post-operative dietary \& exercise recommendations for the duration of the study.
  3. Subjects age >=18 years old.
  4. Hepatic steatosis from NAFLD, as defined by a controlled attenuation parameter ≥ 280 dB/m without alternate cause of liver disease measured by a Fibroscan XL.
  5. ≥ 30kg/m2
  6. If female, be either , surgically sterile, or agree to practice during year of study and have negative serum HCG at screening/baseline.
  7. Absence of current severe systemic disease (including, but not limited to: coronary artery disease, , congestive heart failure, cancer, and chronic renal disease).
  8. Agrees not to undergo any additional weight loss interventional procedures or liposuction for 12 months following study enrollment.
  9. Have not taken any prescription or over-the-counter weight loss medications OR those that can suppress appetite/induce weight loss for at least 6 months and agrees not to utilize for 12 months following study enrollment (including all stimulant medication).
  10. Subjects must be willing to possibly forego any future weight loss procedures (i.e. Vertical Sleeve Gastrectomy) given the unknown long-term effects.
  11. Residing within a reasonable distance from the Investigator's treating office (\~50 miles) and willing and able to travel to the Investigator's office to complete all routine follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. History of (or intra-operative evidence of) prior bariatric, gastric or esophageal surgery.
  2. Esophageal stricture or other anatomy and/or condition that could preclude passage of endoluminal instruments or procedure execution.
  3. Moderate gastro-esophageal reflux disease (GERD), defined as symptoms that cause subject severe discomfort, compromise performance of daily activities, and/or condition is not entirely controlled with drug therapy.
  4. Large hiatal hernia (>3 cm) by history or as determined by pre-enrollment endoscopy.
  5. Pancreatic insufficiency/disease.
  6. History of gastroparesis or symptoms that would be suggestive of gastroparesis or generalized dysmotility (e.g. esophago-gastric motility issues and lower esophageal sphincter abnormalities).
  7. Pregnancy or plans of pregnancy in the next 12 months.
  8. History of a known diagnosis or pre-existing symptom of rheumatoid arthritis, scleroderma, system lupus, or other connective tissue disorder.
  9. medications or systemic (i.e., oral prednisone) within 6 months of Visit 1. Intranasal/inhaled steroids are acceptable.
  10. Unable or unwilling to avoid use of aspirin and/or non-steroidal anti-inflammatory drugs (NSAIDs), or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study.
  11. History of inflammatory disease of the GI tract; coagulation disorders; hepatic insufficiency or cirrhosis.
  12. Active gastric erosion, lesion, or gastric/duodenal ulcer.
  13. History of or current or coagulation dysfunction, such as hemophilia.
  14. History or present use of insulin or insulin derivatives for treatment of diabetes.
  15. Type II Diabetes Mellitus (as defined by HgbA1c >6.5%) for greater than 11 years at the time of enrollment.
  16. If smoker, plans to quit smoking in the year after enrollment.
  17. Portal hypertension and/or varices.
  18. Patient has a history of drug or alcohol abuse or positive at screening for drugs of abuse.
  19. Present or history of psychosis, bipolar disease, or obsessive-compulsive disorder after pre-enrollment history and medical /psychological assessment.
  20. Beck Depression Inventory (Short) Score ≥ 12 and/or uncontrolled depression after pre-enrollment psychological and medical assessment. 1
  21. Patient score >2 in any of the 9 identified symptoms on the Gastroparesis Cardinal Symptom Index (GCSI)
  22. Non-ambulatory or has significant impairment of mobility (i.e. cannot ambulate for 30 minutes).
  23. Known hormonal or genetic cause for obesity including untreated hypothyroidism (TSH >5.0 U/ml).
  24. Participating in another clinical study.
  25. Subjects with a personal history of allergic/anaphylactic reactions including to the drugs or materials that will be utilized in the study procedure.
  26. Physician's assessment that the subject is not an appropriate candidate.

    -

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    POSE2.0

    This is the arm that got the POSE2.0 procedure. The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA). This device is registered and commercially available in the United Arab Emirates for the management of obesity.

    Procedure: POSE2.0 procedure · Behavioral: Life style and behavioral intervention

  • Active comparator
    Life style and behavioral intervention

    This is the comparator arm that received lifestyle modification alone for weight loss and NAFLD management (representing the comparative control group). This group underwent the same lifestyle program and clinical follow-up as the POSE2.0, but under a parallel standard clinical care pathway, which is the standard clinical pathway in the hospital this study was conducted in.

    Behavioral: Life style and behavioral intervention

Interventions

  • ProcedurePOSE2.0 procedure

    The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)

  • BehavioralLife style and behavioral intervention

    The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.

06

What researchers measure

Primary outcomes

  1. Change in controlled attenuation parameter (CAP)

    Measured by Fibroscan XL

    Time frame: 12 months

  2. Change in liver stiffness

    Measured by Fibroscan XL

    Time frame: 12 months

Secondary outcomes

  1. Percent resolution of hepatic steatosis at 12 months

    Measured by fibroscan XL

    Time frame: 12 months

Other outcomes

  1. Change in total body weight loss (TBWL) in each arm

    Time frame: 12 months

07

Study locations

1 site
  • Obaidulla Hospital, Emirates Health Services, Ministry of Health, United Arab Emirates
    Ras Al Khaimah, United Arab Emirates
08

References and documents

Individual participant data

Plan to share: Yes — Select IPD could be shared after approval of the UAE Ministry of Health and after signing a data-sharing agreement.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: Data is available for the next 2 years.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Mar 2022, 25 months.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 25 months is close to that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 10, 2022
StartActual
Jan 20, 2020
Primary completionActual
Mar 15, 2022
CompletionActual
Sep 1, 2022
Last update
Nov 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05611567
Lead sponsor
Emirates Health Services (EHS)
Collaborators
Mayo Clinic
Responsible party
Mariam Salem Alkhatry (Chair of Gastroenterology, Emirates Health Services (EHS)) — Principal investigator
First posted
Nov 10, 2022
Start date
Jan 20, 2020
Primary completion
Mar 15, 2022
Completion
Sep 1, 2022
Last update
Nov 10, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion